1. Home
  2. CRNX vs BHF Comparison

CRNX vs BHF Comparison

Compare CRNX & BHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

N/A

Current Price

$38.65

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Logo Brighthouse Financial Inc.

BHF

Brighthouse Financial Inc.

N/A

Current Price

$61.94

Market Cap

3.7B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CRNX
BHF
Founded
2008
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Life Insurance
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.7B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
CRNX
BHF
Price
$38.65
$61.94
Analyst Decision
Strong Buy
Hold
Analyst Count
8
8
Target Price
$76.75
$57.71
AVG Volume (30 Days)
982.0K
428.6K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,039,000.00
N/A
Revenue This Year
$720.10
$27.10
Revenue Next Year
$184.67
$1.09
P/E Ratio
N/A
$4.34
Revenue Growth
N/A
N/A
52 Week Low
$25.83
$43.16
52 Week High
$57.99
$66.33

Technical Indicators

Market Signals
Indicator
CRNX
BHF
Relative Strength Index (RSI) 49.18 64.55
Support Level $33.19 $59.04
Resistance Level $45.32 $62.63
Average True Range (ATR) 1.42 0.56
MACD -0.03 0.06
Stochastic Oscillator 31.19 93.27

Price Performance

Historical Comparison
CRNX
BHF

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About BHF Brighthouse Financial Inc.

Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.

Share on Social Networks: